ethylmethylhydroxypyridine-succinate and Hypertension

ethylmethylhydroxypyridine-succinate has been researched along with Hypertension* in 2 studies

Trials

1 trial(s) available for ethylmethylhydroxypyridine-succinate and Hypertension

Article	Year
[Efficiency of combined therapy with myocardial cytoprotector mexicor in hypertensive patients with acute cerebrovascular disturbances]. Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery, 2008, Volume: 14, Issue:4 Sixty hypertensive patients (mean age 64.9 +/- 1.5) with acute ischemic stroke were randomized into 2 groups. Both groups received conventional therapy (Aspirin Cardio, Trental, Prestarium, Arifon), which in the test group was added by Mexicor (0.3 gper day for 3 weeks). Circadian blood pressure (BP) and its variability were monitored in all patients at 1, 5, 10, 14, and 21 days after the stroke. NIH Stroke Scale, the Barthel ADL Index, Rankin Scale, Mini-Mental State Examination (MMSE) and Frontal Assessment Battery (FAB) were used for the neurological status assessment. Mexicor was shown to accelerate the systolic and diastolic BP lowering, reduction of BP variability (mainly nocturnal) and improvement of circadian BP profile (more patients showed dipper type hypertension and less - non-dipper, over-dipper and night-peaker patterns, compared with the control group). Mexicor had a positive effect on neurological status, cognitive function and focal neurological deficit severity. Topics: Acute Disease; Aged; Antihypertensive Agents; Blood Pressure; Brain Ischemia; Cognition; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypertension; Infusions, Intravenous; Male; Middle Aged; Neuroprotective Agents; Pyridines; Treatment Outcome	2008

Article

Year

[Efficiency of combined therapy with myocardial cytoprotector mexicor in hypertensive patients with acute cerebrovascular disturbances].

Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery, 2008, Volume: 14, Issue:4

Sixty hypertensive patients (mean age 64.9 +/- 1.5) with acute ischemic stroke were randomized into 2 groups. Both groups received conventional therapy (Aspirin Cardio, Trental, Prestarium, Arifon), which in the test group was added by Mexicor (0.3 gper day for 3 weeks). Circadian blood pressure (BP) and its variability were monitored in all patients at 1, 5, 10, 14, and 21 days after the stroke. NIH Stroke Scale, the Barthel ADL Index, Rankin Scale, Mini-Mental State Examination (MMSE) and Frontal Assessment Battery (FAB) were used for the neurological status assessment. Mexicor was shown to accelerate the systolic and diastolic BP lowering, reduction of BP variability (mainly nocturnal) and improvement of circadian BP profile (more patients showed dipper type hypertension and less - non-dipper, over-dipper and night-peaker patterns, compared with the control group). Mexicor had a positive effect on neurological status, cognitive function and focal neurological deficit severity.

Topics: Acute Disease; Aged; Antihypertensive Agents; Blood Pressure; Brain Ischemia; Cognition; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypertension; Infusions, Intravenous; Male; Middle Aged; Neuroprotective Agents; Pyridines; Treatment Outcome

2008

Other Studies

1 other study(ies) available for ethylmethylhydroxypyridine-succinate and Hypertension

Article	Year
Effect of phosphocreatine and ethylmethylhydroxypyridine succinate on the expression of Bax and Bcl-2 proteins in left-ventricular cardiomyocytes of spontaneously hypertensive rats. Bulletin of experimental biology and medicine, 2015, Volume: 158, Issue:3 We studied the effect of phosphocreatine and ethylmethylhydroxypyridine succinate on the expression of Bax and Bcl-2 proteins in left-ventricular cardiomyocytes of spontaneously hypertensive rats (SHR). Both drugs have no effect on the expression of Bcl-2, but significantly reduce the level of Bax protein (phosphocreatine produces more pronounced effect). These data attest to an important role of energy deficit and oxidative stress in the induction of cardiomyocyte apoptosis in genetically determined arterial hypertension. Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Gene Expression Regulation; Heart Ventricles; Hypertension; Male; Myocytes, Cardiac; Phosphocreatine; Picolines; Proto-Oncogene Proteins c-bcl-2; Pyridines; Rats; Rats, Inbred SHR	2015

Article

Year

Effect of phosphocreatine and ethylmethylhydroxypyridine succinate on the expression of Bax and Bcl-2 proteins in left-ventricular cardiomyocytes of spontaneously hypertensive rats.

Bulletin of experimental biology and medicine, 2015, Volume: 158, Issue:3

We studied the effect of phosphocreatine and ethylmethylhydroxypyridine succinate on the expression of Bax and Bcl-2 proteins in left-ventricular cardiomyocytes of spontaneously hypertensive rats (SHR). Both drugs have no effect on the expression of Bcl-2, but significantly reduce the level of Bax protein (phosphocreatine produces more pronounced effect). These data attest to an important role of energy deficit and oxidative stress in the induction of cardiomyocyte apoptosis in genetically determined arterial hypertension.

Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Gene Expression Regulation; Heart Ventricles; Hypertension; Male; Myocytes, Cardiac; Phosphocreatine; Picolines; Proto-Oncogene Proteins c-bcl-2; Pyridines; Rats; Rats, Inbred SHR

2015